Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis

Abstract Introduction Deucravacitinib, an oral tyrosine kinase 2 (TYK2) inhibitor, is approved in the United States to treat adults with moderate-to-severe plaque psoriasis (PsO). This study compared the long-term efficacy of deucravacitinib and adalimumab using results from long-term extension (LTE...

Полное описание

Библиографические подробности

Главные авторы:	April W. Armstrong, Sang Hee Park, Vardhaman Patel, Malcolm Hogan, Wei-Jhih Wang, David Davidson, Viktor Chirikov
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Adis, Springer Healthcare 2023-07-01
Серии:	Dermatology and Therapy
Предметы:	Adalimumab Deucravacitinib Indirect comparison MAIC Plaque psoriasis
Online-ссылка:	https://doi.org/10.1007/s13555-023-00977-1
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!